A preparation method of a substituted borate ester compound and its crystal form
By reacting the compound of formula (B) with citric acid to form the compound of formula (A) and optimizing its crystalline form, the existing proteasome inhibitor stability and pharmacokinetic problems are solved, and a more effective proteasome inhibition effect is achieved. .
Patent Information
- Application Number
- CN202110844510.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-12-05
- Filing Date
- 2018-11-21
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2038-11-21
AI Technical Summary
The existing proteasome inhibitors have low in vivo stability, short plasma half-life, fast clearance rate, and it is difficult to effectively inhibit proteasome activity, resulting in insufficient pharmacodynamic performance.
By reacting the compound of formula (B) with citric acid to form the compound of formula (A) and optimizing it through different solvents and conditions, crystalline forms of compounds of formula (A-1) and formula (A-2) are prepared to improve their stability and pharmacokinetic properties.
It improves the stability and pharmacokinetic properties of proteasome inhibitors, extends the half-life, reduces the clearance rate, enhances the inhibitory activity on proteasomes, and improves pharmacodynamic performance.
Smart Images

Figure CN113603713B_ABST
Abstract
Description
[0001] This application is a divisional application of an invention patent application with an application date of November 21, 2018, application number 201811390368.8, and invention name “A method for preparing a substituted borate compound and its crystal form”. Technical Field
[0002] The present invention belongs to the field of medical technology, and in particular relates to a high-purity substituted borate compound and a preparation method and a crystal form thereof. The present invention also provides a pharmaceutical composition comprising the compound of the present invention, and a method for using the composition to treat various diseases. Background Art
[0003] The proteasome is a large multivalent complex enzyme that participates in many important physiological and biochemical processes in cells, such as DNA repair, cell cycle operation, signal transduction, antigen presentation, transmembrane localization of proteins, etc. It plays a major role in balancing important intracellular enzymes. The function of the proteasome is achieved through the ubiquitin-proteasome pathway (UPP). UPP not only catalyzes the degradation of abnormal proteins, but also participates in many regulatory and protein renewal and processing processes. The catalytic processes of these proteins involve important biochemical mechanisms for the onset of human diseases.
[0004] Proteasome inhibitors inhibit the activity of proteasomes, thereby affecting the expression of cell growth-related proteins, cytokines and signaling molecules, interfering with the original proliferation, differentiation and apoptosis processes of cells, and inhibiting the growth of tumor cells more significantly.
[0005] Proteasome inhibitors mainly include peptide aldehydes, peptide boronic acids, peptide epoxyketones, peptide vinyl sulfones, β-lactones and other compounds. Bortezomib (VELCADE), a peptide boronic acid proteasome inhibitor, is the first proteasome inhibitor used in clinical practice. It was approved by the U.S. Food and Drug Administration (FDA) in 2003 and 2006 for the treatment of multiple myeloma (MM) and mantle cell lymphoma (MCL), respectively. Carfilzomib (Kyprolis), a peptide epoxyketone peptide proteasome inhibitor, was approved by the FDA in 2012 for the treatment of multiple myeloma, becoming the second marketed proteasome anti-tumor drug. Ixazomib citrate (Ninlaro), a peptide boronic acid proteasome inhibitor, was approved by the FDA in 2015 for the treatment of multiple myeloma, becoming the second marketed peptide boronic acid proteasome inhibitor. Marketed drugs and reported boronic acid proteasome inhibitors such as WO2005 / 021558, WO2005 / 016859, WO2006 / 086600, WO2009 / 02044, WO2010 / 012222, WO2011 / 109355, WO2011 / 026349, WO2011 / 087822, WO2013 / 092979 and other peptide skeleton proteasome inhibitors have low in vivo stability, short half-life in plasma, and fast clearance rate (Miller et al. J Med Chem, 2015, 58: 2036-41).
[0006] Therefore, there is still a need in the art to develop proteasome inhibitors that have inhibitory activity on proteasome or better pharmacodynamic properties. Summary of the invention
[0007] In one aspect, the present invention relates to a method for preparing a compound of formula (A) or a crystalline form thereof:
[0008]
[0009] wherein n and m are independently selected from 0 or 1; and n and m are different,
[0010] The method comprises the following steps:
[0011] a) reacting a compound of formula (B) with citric acid to form a compound of formula (A):
[0012]
[0013] b) optionally crystallizing the compound of formula (A).
[0014] In another aspect, the present invention relates to a compound of formula (A-1), or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof.
[0015]
[0016] In another aspect, the present invention also relates to a crystalline compound of formula (A-1),
[0017]
[0018] It is characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163, 28.8°. θ ±0.2 θ 2 θ , which is measured by diffractometer using Cu-Kα radiation on Wavelength determination.
[0019] In another aspect, the present invention provides a crystalline compound of formula (A-2),
[0020]
[0021] It is characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840°. θ ±0.2 θ 2 θ , which is measured by diffractometer using Cu-Kα radiation on Wavelength determination.
[0022] On the other hand, the present invention provides a method for preparing the pharmaceutical composition as described above, comprising the following steps: mixing a pharmaceutically acceptable excipient with the compound of the present invention, or a crystal form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt to form a pharmaceutical composition.
[0023] On the other hand, the present invention provides a pharmaceutical composition containing a compound of the present invention and a pharmaceutically acceptable excipient. In a specific embodiment, the compound of the present invention is provided in the pharmaceutical composition in an effective amount. In a specific embodiment, the compound of the present invention is provided in a therapeutically effective amount. In a specific embodiment, the compound of the present invention is provided in a preventive effective amount. In another embodiment, the pharmaceutical composition is an injection, capsule, tablet, pill, powder or granule. In another embodiment, the pharmaceutical composition also contains another therapeutic drug, and the other therapeutic drug is a drug for cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis, and prostate disease.
[0024] In another aspect, there is provided a use of the compound described in the first aspect of the present invention, or a crystal form thereof, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof, which is used to prepare a pharmaceutical composition for inhibiting proteasomes. In another embodiment, the compound can be used to treat and prevent diseases associated with proteasome targets. In another embodiment, the pharmaceutical composition is used to treat and prevent the following diseases: cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis, or prostate disease. Preferably, the cancer includes but is not limited to: multiple myeloma, non-small cell lung cancer, uterine cancer, rectum, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumors, solid tumors, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer.
[0025] In another aspect, the present invention provides a method of treatment, comprising the steps of administering the compound of the present invention, or a crystalline form thereof, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof, or administering the pharmaceutical composition of the present invention to a subject in need of treatment, thereby inhibiting the proteasome. Preferably, the disease comprises cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis, or prostate disease. Preferably, the cancer comprises, but is not limited to, multiple myeloma, non-small cell lung cancer, uterine cancer, rectum, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumors, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer. DETAILED DESCRIPTION OF THE INVENTION
[0027] In one aspect, the present invention relates to a method for preparing a compound of formula (A) or a crystalline form thereof:
[0028]
[0029] wherein n and m are independently selected from 0 or 1; and n and m are different,
[0030] The method comprises the following steps:
[0031] a) reacting a compound of formula (B) with citric acid to form a compound of formula (A):
[0032]
[0033] b) optionally crystallizing the compound of formula (A).
[0034] In another aspect, the present invention relates to a method for preparing a compound of formula (A-1) or a crystalline form thereof:
[0035]
[0036] The method comprises the following steps:
[0037] a) reacting a compound of formula (B) with citric acid to form a compound of formula (A-1), wherein the solvent is dioxane:
[0038]
[0039] b) optionally crystallizing the compound of formula (A-1).
[0040] Preferably, the solvent in step a) is 1,4-dioxane.
[0041] Preferably, the reaction temperature of step a) is from 40°C to the boiling temperature of dioxane (101.1°C), preferably from 40°C to 80°C.
[0042] Preferably, the reaction temperature in step a) is 80°C.
[0043] Preferably, step a) is to add the compound of formula (B) and citric acid into a solvent, and stir the reaction at 80° C. until the raw materials react completely.
[0044] Preferably, in step b), the solvent of step a) is removed, and ethyl acetate is added at room temperature and stirred until a solid is precipitated.
[0045] Preferably, in step b), ethyl acetate is added at room temperature and stirred for 12 hours to precipitate a solid which is then filtered off.
[0046] In another aspect, the present invention relates to a method for preparing a compound of formula (A-2) or a crystalline form thereof:
[0047]
[0048] The method comprises the following steps:
[0049] a) reacting a compound of formula (B) with citric acid to form a compound of formula (A-2), wherein the solvent is selected from methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, methyl tert-butyl ether and mixtures thereof:
[0050]
[0051] b) optionally crystallizing the compound of formula (A-2).
[0052] Preferably, the reaction temperature of step a) is from 40°C to the boiling temperature of the solvent, preferably from 40°C to, for example, 80°C.
[0053] Preferably, step a) is to add the compound of formula (B) and citric acid into a solvent, and stir the reaction until the raw materials react completely.
[0054] Preferably, in step b), the solvent of step a) is removed, and ethyl acetate is added at room temperature and stirred until a solid is precipitated.
[0055] Preferably, the solvent in step a) is ethyl acetate.
[0056] Preferably, the reaction temperature in step a) is 70°C.
[0057] Preferably, the compound of formula (B) and citric acid are added to a solvent, stirred at 70° C. for 10 minutes, cooled to room temperature and stirred until a solid is precipitated.
[0058] Preferably, the temperature is lowered to room temperature and stirred for 12 hours, and the precipitated solid is filtered off.
[0059] In another aspect, the present invention relates to a compound of formula (A) or a crystal thereof prepared by any one of the above methods.
[0060] In another aspect, the present invention relates to a compound of formula (A-1), or a crystalline form, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof
[0061]
[0062] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-1),
[0063]
[0064] The invention is characterized in that the X-ray powder diffraction pattern includes the following peaks: 6.361, 8.06, 16.137, 17.56, 19.001, 20.201, 24.88, 25.358°2θ±0.2°2θ, and the wavelength used on the diffractometer is Cu-Kα radiation measurement.
[0065] On the other hand, the present invention relates to a crystalline form I of a compound of formula (A-1), characterized in that an X-ray powder diffraction pattern comprises the following peaks: 6.361, 8.06, 10.599, 14.80, 16.137, 17.56, 19.001, 20.201, 21.02, 24.88, 25.358°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
[0066] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-1), characterized in that the X-ray powder diffraction pattern comprises the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163, 28.2°. θ ±0.2 θ 2 θ , which uses a wavelength of Cu-Kα radiation measurement.
[0067] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-1), wherein the diffraction pattern is substantially as follows Figure 1 shown.
[0068] In another aspect, the present invention relates to Form I of the compound of formula (A-1), characterized by a differential scanning calorimetry (DSC) curve comprising endotherms at about 197.9°C and about 249.7°C.
[0069] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-1), wherein the DSC curve is substantially as follows Figure 2 shown.
[0070] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-2),
[0071]
[0072] The invention is characterized in that the X-ray powder diffraction pattern includes the following peaks: 5.740, 7.517, 11.458, 19.438, 19.801 and 22.262°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
[0073] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-2), characterized in that an X-ray powder diffraction pattern comprises the following peaks: 5.740, 7.517, 11.458, 12.439, 16.578, 19.438, 19.801, 22.262 and 22.999°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
[0074] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-2), characterized in that the X-ray powder diffraction pattern comprises the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840°. θ ±0.2 θ 2 θ , which uses a wavelength of Cu-Kα radiation measurement.
[0075] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-2), wherein the diffraction pattern is substantially as follows Figure 3 shown.
[0076] In another aspect, the present invention relates to Form I of the compound of formula (A-2), characterized by a differential scanning calorimetry (DSC) curve comprising endotherms at about 224.6°C, about 237.0°C, and about 253.5°C.
[0077] In another aspect, the present invention relates to a crystalline form I of a compound of formula (A-2), wherein the DSC curve is substantially as follows Figure 4 shown.
[0078] On the other hand, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (A) or its crystal prepared by the preparation method described in the present invention, or crystal form I of the compound of formula (A-1) or crystal form I of the compound of formula (A-2).
[0079] In another aspect, the present invention relates to the use of the compound of formula (A) or its crystal prepared by the preparation method of the present invention, or the crystalline form I of the compound of formula (A-1) or the crystalline form I of the compound of formula (A-2) in the preparation of drugs for treating and preventing proteasome-related diseases.
[0080] On the other hand, the present invention relates to the use of the compound of formula (A) or its crystal prepared by the preparation method of the present invention, or the crystalline form I of the compound of formula (A-1), or the crystalline form I of the compound of formula (A-2) in the preparation of drugs for treating and preventing cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis or prostate disease.
[0081] In a further aspect, the cancer is selected from multiple myeloma, non-small cell lung cancer, uterine cancer, colorectal cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumors, kidney cancer, blood cancer, liver cancer, stomach cancer, or pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 The X-ray powder diffraction (XRPD) of Form I of the compound of formula (A-1) is shown.
[0083] Figure 2 The differential scanning calorimeter (DSC) curve and the thermogravimetric analysis (TGA) curve of the crystalline form I of the compound of formula (A-1) are shown.
[0084] Figure 3 The X-ray powder diffraction (XRPD) of Form I of the compound of formula (A-2) is shown.
[0085] Figure 4 The differential scanning calorimeter (DSC) curve and the thermogravimetric analysis (TGA) curve of the crystalline form I of the compound of formula (A-2) are shown. DETAILED DESCRIPTION
[0086] Definitions and abbreviations
[0087] Herein, unless otherwise specified, "deuterated" means that one or more hydrogen atoms in a compound or group are replaced by deuterium; deuterated can be monosubstituted, disubstituted, polysubstituted or fully substituted. The term "one or more deuterated" and "one or more deuterated" can be used interchangeably.
[0088] Herein, unless otherwise specified, the deuterium isotope content of deuterium at the deuterated position is at least 0.015% greater than the natural deuterium isotope content, preferably greater than 30%, more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, and more preferably greater than 99%.
[0089] As used herein, unless otherwise specified, a "non-deuterated compound" refers to a compound containing deuterium atoms at a ratio not higher than the natural deuterium isotope content (0.015%).
[0090] Herein, the term "independently selected from" means that multiple groups are selected from certain substituents, and there is no connection between the groups. For example, "m, n are independently selected from 0 or 1" means that m is selected from 0 or 1, n is selected from 0 and 1, and there is no connection between m and n.
[0091] As used herein, the term "compound of the present invention" refers to a compound of formula (I). The term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compound of formula (I).
[0092] Wherein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with tissues of humans and lower animals without excessive toxicity, irritation, allergic reactions, etc., and are commensurate with a reasonable benefit / risk ratio within the scope of sound medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and inorganic and organic bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or salts formed with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Also included are salts formed using conventional methods in the art, for example, ion exchange methods. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluconate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Pharmaceutically acceptable salts derived from suitable bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium salts, and the like. Other pharmaceutically acceptable salts include non-toxic ammonium salts, quaternary ammonium salts and amine cations formed with counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates, if appropriate.
[0093] The term "solvate" refers to a complex formed by the coordination of the compound of the present invention with solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the coordination of the compound of the present invention with water.
[0094] The present invention also includes isotopically labeled compounds that are equivalent to the original compounds disclosed herein. Examples of isotopes that can be listed as compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine isotopes, such as 2 H, 3 H, 13 C, 14 C, 15 N, 17 Oh, 18 Oh, 31 P, 32 P, 35 S, 18 F and 36 The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, which contain isotopes or other isotopic atoms of the above compounds, are within the scope of the present invention. Certain isotope-labeled compounds of the present invention, such as 3 H and 14 Radioisotopes of C are also included and are useful in tissue distribution experiments of drugs and substrates. 3 H and carbon-14, i.e. 14 C, they are easier to prepare and detect, and are the first choice among isotopes. Isotope-labeled compounds can be prepared by general methods, by replacing readily available isotope-labeled reagents with non-isotopic reagents, using the schemes shown in the examples.
[0095] Abbreviations
[0096] EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
[0097] HOBT: 1-Hydroxybenzotriazole
[0098] TBTU: O-Benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate
[0099] DCC: dicyclohexylcarbodiimide
[0100] HBTU: O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate
[0101] HCTU: 6-Chlorobenzotriazole-1,1,3,3-tetramethyluronium hexafluorophosphate
[0102] TCTU: O-(6-chlorobenzotriazol-1-yl)-1,1,3,3-N,N,N',N'-tetramethyluronium tetrafluoroborate HATU: 2-(7-azobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
[0103] PyBOP: benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
[0104] NMM: N-methylmorpholine
[0105] NEA: Triethylamine
[0106] DIPEA: N,N-diisopropylethylamine
[0107] PCl3: Phosphorus trichloride
[0108] PCl5: Phosphorus pentachloride
[0109] NaOH: Sodium hydroxide
[0110] KOH: Potassium Hydroxide
[0111] Preparation method
[0112] The methods disclosed herein and their conventional modifications can be used to carry out the methods of the present invention, which will be apparent from the disclosure herein and methods well known in the art. In addition to those taught herein, conventional and well-known synthetic methods can be used. The synthesis of typical compounds described herein (e.g., formula (A-1) and formula (A-2)) can be accomplished as described in the following examples.
[0113] Typical embodiments of compounds according to the present invention can be synthesized using the general reaction scheme described below. It will be apparent from the description herein that the general scheme can be changed by replacing the starting raw materials with other substances with similar structures, thereby generating corresponding different products. Given the desired product in which the substituent is defined, the desired starting raw materials can usually be determined by inspection. The starting raw materials are usually obtained from commercial sources or synthesized using disclosed methods. In order to synthesize the compounds of the disclosed embodiments, the structure of the compound to be synthesized will provide the identification of each substituent. In view of the embodiments herein, the properties of the final product will usually show the characteristics of the desired starting raw materials through a simple inspection process.
[0114] Compounds disclosed herein can be prepared from readily available starting materials using, for example, the following general methods and processes. It should be understood that, given typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.), other process conditions may also be used unless otherwise indicated. Optimal reaction conditions may vary with the specific reactants or solvents used, but those skilled in the art may determine the conditions by conventional optimization procedures.
[0115] In addition, the compounds of the present disclosure may contain one or more chiral centers. Therefore, if desired, the compound can be prepared as a pure stereoisomer, or separated into pure stereoisomers, i.e., as independent enantiomers or diastereomers or as a mixture enriched in stereoisomers. Unless otherwise indicated, all these stereoisomers (and enriched mixtures) are included within the scope of the present invention. For example, optional active starting materials or stereoselective reagents well known in the art can be used to prepare pure stereoisomers (or enriched mixtures). Alternatively, the racemic mixture of the compound can be separated using, for example, chiral column chromatography, chiral resolving agents, etc.
[0116] The starting materials for the following reactions are generally known compounds or can be prepared by known methods or obvious modifications thereof. For example, many starting materials are available from commercial suppliers such as Shanghai Tebo Chemical Technology Co., Ltd. (Shanghai, China), Sane Chemical Technology (Shanghai) Co., Ltd. (Shanghai, China), Shanghai Houpu Chemical Technology Co., Ltd. (Shanghai, China), Shanghai Jinlu Pharmaceutical Technology Co., Ltd. (Shanghai, China), Anhui Dexinjia Biopharmaceutical Co., Ltd. (Anhui, China), Tianjin Famoxi Pharmaceutical Technology Co., Ltd. (Tianjin, China), Hunan Hezhong Pharmaceutical Technology Co., Ltd. (Hunan, China). Others can be prepared by the operations described in standard references or their obvious modifications, such as Fieser and Fieser's Reagents for Organic Synthesis (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds (Elsevier Science Publishers, 1989), Organic Reactions (John Wiley and Sons, 1991), March's Advanced Organic Chemistry (John Wiley and Sons, 5 th Edition, 2001) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0117] In each exemplary scheme, it may be advantageous to separate the reaction products from each other and / or from the starting materials. The desired product of each step or series of steps is separated and / or purified (hereinafter referred to as separation) to the desired degree of homogeneity by techniques common in the art. Typically, such separations include multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation or chromatography. Chromatography can include any number of methods, including, for example: reverse phase and normal phase chromatography; size exclusion chromatography; ion exchange chromatography; high, medium and low pressure liquid chromatography and equipment; small-scale analytical chromatography; simulated moving bed (SMB) and preparative thin layer or thick layer chromatography, as well as small-scale thin layer and flash chromatography techniques.
[0118] Another class of separation methods involves treating the mixture with a reagent that selectively binds to or separates from the product, unreacted starting material, reaction byproducts, etc. Such reagents include adsorbents or absorbents, such as activated carbon, molecular sieves, ion exchange media, etc. Alternatively, the reagent can be an acid (in the case of a basic substance), a base (in the case of an acidic substance), a binding agent such as an antibody, a binding protein, a selective chelating agent such as a crown ether, a liquid / liquid extrusion agent (LIX), etc.
[0119] The selection of an appropriate separation method depends on the properties of the substances involved. For example, boiling point and molecular weight in distillation and sublimation, the presence or absence of polar functional groups in chromatography, the stability of materials in acidic and basic media in multiphase extraction, etc. One skilled in the art will apply the technique most likely to achieve the desired separation.
[0120] A single stereoisomer, such as an enantiomer, which is substantially free of its stereoisomers, can be obtained by resolution of the racemic mixture using, for example, a method for forming diastereomers using an optically active resolving agent (Stereochemistry of Carbon Compounds, (1962), EL Elliel, McGraw Hill; Lochmuller, CH, (1975) J. Chromatogr., 113: (3) 283-302). The racemic mixture of the chiral compounds of the present invention can be separated and resolved by any suitable method, including: (1) forming ionic diastereomeric salts with chiral compounds and separating by fractional crystallization or other methods; (2) forming diastereomeric compounds with chiral derivatizing agents, separating diastereomers, and converting to pure stereoisomers; and (3) separating substantially pure or enriched stereoisomers directly under chiral conditions.
[0121] As described above, the present disclosure provides, in some embodiments, a method for preparing a compound of formula (A). In one embodiment, the present invention provides a method for preparing the compound of formula (A) or a crystalline form thereof,
[0122]
[0123] wherein n and m are independently selected from 0 or 1; and n and m are different,
[0124] The method comprises the following steps:
[0125] a) combining a compound of formula B with citric acid to form a compound of formula A:
[0126]
[0127] Wherein, n and m are independently selected from 0 or 1; and n and m are different.
[0128] b) optionally crystallizing the compound of formula (A).
[0129] In some embodiments, the reaction conditions of step a) include a solvent, preferably the solvent is selected from methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dioxane, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, tert-butyl methyl ether and mixtures thereof; more preferably, the solvent is dioxane; more preferably, the solvent is ethyl acetate.
[0130] In some embodiments, the reaction conditions of step a) include operating at about 40°C to about the boiling temperature of the solvent (preferably about 40°C to about 80°C); more preferably, the temperature is about 80°C; more preferably, the temperature is 70°C.
[0131] The applicant unexpectedly discovered that for the deuterated compound of the present invention (compound of formula (B)), it is difficult to form the compound of formula (A-1) according to the method of the prior art. For example, by referring to the method in WO2009154737A1 (such as paragraphs
[0314] and
[0318] , using ethyl acetate as a solvent), after the addition of the materials at 74°C, whether the reaction solution is cooled uncontrolled or slowly cooled to about 60°C at a rate of 0.33°C / min and reacted for 3 hours, and then cooled to 25°C at a rate of 0.12°C / min, only the compound of formula (A-2) can be obtained. In addition, the applicant has also tried a variety of other solvents, and all of them have obtained the compound of formula (A-2).
[0132] Therefore, in some embodiments, when the reaction solvent of step a) is selected from methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, tert-butyl methyl ether and mixtures thereof, the compound of formula (B) reacts with citric acid to form a compound of formula (A-2).
[0133] In other embodiments, the applicant unexpectedly discovered that when the reaction solvent of step a) is dioxane (eg, 1,4-dioxane), the compound of formula (B) reacts with citric acid to form the compound of formula (A-1).
[0134] In some embodiments, the method for preparing the compound of formula (A) or its crystalline form according to the present invention further comprises the following steps:
[0135] c) combining the compound of formula C with a deprotecting agent to form a compound of formula B:
[0136]
[0137] In some embodiments, the reaction conditions of step c) include an organoboron reagent; preferably, the organoboron reagent is isobutylboronic acid.
[0138] In some embodiments, the reaction conditions of step c) include a lower alkanol; preferably, the lower alkanol is selected from methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol or pentanol; more preferably, the lower alkanol is methanol.
[0139] In some embodiments, the reaction conditions of step c) include aqueous inorganic acid solution; preferably, the inorganic acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid; more preferably, the inorganic acid is selected from hydrochloric acid.
[0140] In some embodiments, the method for preparing the compound of formula (A) or its crystalline form according to the present invention further comprises the following steps:
[0141] d) combining a compound of formula E with a compound of formula D to form a compound of formula C:
[0142]
[0143] In some embodiments, the reaction conditions of step d) include a peptide coupling reagent; preferably, the peptide coupling reagent is selected from EDC and HOBT, TBTU, DCC and HOBT, HBTU, HCTU, TCTU, HATU or PyBOP; more preferably, the peptide coupling reagent is selected from TBTU, HBTU, HCTU, TCTU, HATU; most preferably, the peptide coupling reagent is TBTU.
[0144] In some embodiments, the reaction conditions of step d) include a base; preferably, the base is selected from NMM, TEA and DIPEA; more preferably, the base is selected from DIPEA.
[0145] In some embodiments, the reaction conditions of step d) include a solvent; preferably, the solvent is selected from dichloromethane, tetrahydrofuran, toluene, benzene, acetonitrile, dioxane and N,N-dimethylformamide, or a mixture thereof; more preferably, the solvent is selected from N,N-dimethylformamide.
[0146] In some embodiments, the reaction conditions of step d) include a temperature of about -20°C to about 50°C; preferably, the temperature is selected from about -20°C to about 10°C; more preferably, the temperature is 0°C.
[0147] In some embodiments, the method for preparing the compound of formula (A) or its crystalline form according to the present invention further comprises the following steps:
[0148] e) combining the compound of formula F with glycine-2,2-d2 to form a compound of formula E:
[0149]
[0150] In some embodiments, the reaction conditions of step e) include a base; preferably, the base is selected from NaOH and KOH; more preferably, the base is NaOH.
[0151] In some embodiments, the reaction conditions of step e) include a solvent; preferably, the solvent is selected from tetrahydrofuran, 2-methyltetrahydrofuran, acetone, DMF and DMSO; more preferably, the solvent is selected from tetrahydrofuran, 2-methyltetrahydrofuran and DMF; most preferably, the solvent is selected from tetrahydrofuran.
[0152] In some embodiments, the method for preparing the compound of formula (A) or its crystalline form according to the present invention further comprises the following steps:
[0153] f) combining a compound of formula G with a chlorinating agent to form a compound of formula F:
[0154]
[0155] In some embodiments, the reaction conditions of step f) include a chlorinating agent; preferably, the chlorinating agent is selected from thionyl chloride, oxalyl chloride, PCl3 or PCl5 with or without DMF; more preferably, the chlorinating agent is selected from thionyl chloride or oxalyl chloride; most preferably, the chlorinating agent is selected from thionyl chloride.
[0156] Crystal form
[0157] The present invention provides crystalline forms of the compound of formula (A-1) and the compound of formula (A-2) as specified herein.
[0158] The crystalline compound of formula (A-1), Form I, is characterized by an X-ray powder diffraction pattern comprising the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163, 28.89 θ ±0.2 θ 2 θ , which was measured by diffractometer using Cu-Kα radiation at The crystalline form I of the compound of formula (A-1) is also characterized in that it is substantially as Figure 1 The full X-ray powder diffraction pattern is shown.
[0159] In some embodiments, the crystalline form I of the compound of formula (A-1) is characterized by a differential scanning calorimetry (DSC) curve comprising an endotherm at about 197.9°C and an endotherm at about 249.7°C. The crystalline form I of the compound of formula (A-1) is also characterized in that it is substantially as Figure 2 The DSC curve is shown.
[0160] The crystalline compound of formula (A-2), Form I, is characterized by an X-ray powder diffraction pattern comprising the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840°. θ ±0.2 θ 2 θ , which was measured by diffractometer using Cu-Kα radiation at The crystal form I of the compound of formula (A-2) is also characterized in that it is substantially as Figure 3 The full X-ray powder diffraction pattern is shown.
[0161] In some embodiments, the crystalline form I of the compound of formula (A-2) is characterized by a differential scanning calorimetry (DSC) curve comprising endotherms at about 224.6°C and 237.0°C, and an endotherm at about 253.5°C. The crystalline form I of the compound of formula (A-2) is also characterized in that it is substantially as Figure 4 The DSC curve is shown.
[0162] Pharmaceutical compositions and methods of administration
[0163] Since the compounds of the present invention have excellent inhibitory activity on proteasomes, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable hydrates or solvates, or pharmaceutically acceptable salts, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent, and alleviate diseases mediated by proteasomes. According to the prior art, the compounds of the present invention can be used to treat the following diseases: cancer, cardiovascular disease, obesity, diabetes, and the like.
[0164] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 10-200 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.
[0165] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compound of the present invention and with each other without significantly reducing the efficacy of the compound.
[0166] The terms "carrier", "excipient" or "vehicle" are used interchangeably herein and include any and all solvents, diluents and other liquid carriers, dispersion or suspension aids, surfactants, pH adjusters, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, etc., suitable for the particular dosage form desired. Unless any conventional carrier medium is incompatible with the compounds of the invention, for example by producing any undesirable biological effect or interacting with any other component of the pharmaceutical composition to reduce or inactivate the compound, or to produce harmful substances, its use is considered to be within the scope of the present invention.
[0167] Pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, carbonates, magnesium hydroxide and aluminum glycine, sorbic acid or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, pyrogen-free water, salts or electrolytes such as protamine sulfate, disodium phosphate, disodium hydrogen phosphate, sodium chloride and zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, polyethylene-polyoxypropylene block polymers, lanolin, sugars such as lactose, glucose, sucrose and mannitol, starches such as corn starch and potato starch. Potato starch, cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate, powdered yellow gum: malt, gelatin, talc, excipients such as cocoa butter and suppository wax, oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil, glycols such as propylene glycol and polyethylene glycol, esters such as ethyl oleate and ethyl laurate, agar, alginic acid, isotonic saline, compound sodium chloride injection, alcohols such as ethanol, isopropyl alcohol, hexadecyl alcohol and glycerol, cyclodextrins such as hydroxypropyl β-cyclodextrin and sulfobutyl ether β-cyclodextrin, lubricants such as forget and magnesium stearate, petroleum hydroxy such as mineral oil and vaseline. Colorants, release agents, coating agents, sweeteners, flavorings and fragrances, preservatives and antioxidants may also be present in the composition according to the judgment of the formulator.
[0168] The pharmaceutical composition of the present invention can be prepared by methods well known in the art, such as conventional granulation, mixing, dissolution, encapsulation, lyophilization or emulsification methods, etc. The composition can be produced in various forms, including granules, precipitates or granules, powders, including freeze-dried, rotary-dried or spray-dried powders, amorphous powders, tablets, capsules, syrups, suppositories, injections, emulsions, elixirs, suspensions or solutions.
[0169] The mode of administration of the compounds of the present invention or pharmaceutical composition is not particularly limited. According to a preferred embodiment, the composition of the present invention is formulated for mammals, preferably human medicine. These pharmaceutical compositions of the present invention can be administered orally, extra-digestive, by inhalation spray, topically, rectal, nasal, buccal, vaginally or via an implantable drug box. The term "extra-digestive administration" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intravenously or subcutaneously. The preparation of the present invention can be designed to be short-acting, rapid-release or long-acting. In addition, the compound can be administered locally rather than systemically, for example, at the tumor site (e.g., by injection).
[0170] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, cyclodextrin, dimethylformamide, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters, sorbitan and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, rotants and aromatics.
[0171] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; (c) humectants, such as glycerol; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) solubilizers, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) lubricants, such as calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may also contain a buffer.
[0172] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0173] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0174] Injectable preparations, such as sterile injectable aqueous or oily suspensions, can be prepared using suitable dispersants or wetting agents and suspending agents according to known techniques. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable carriers and solvents that can be used are water, compound sodium chloride injection, and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspension media, and any mild fixed oils can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injections. Injectables can be sterilized, for example, by filtering through bacterial retention or by incorporating a sterilizing agent in the form of a sterile solid composition, which is dissolved or dispersed in sterile water or other sterile injectable media before use. Compositions formulated for parenteral administration can be injected by push or by timed push injection, or can be administered by continuous infusion.
[0175] The dosage form for topical or transdermal administration of the compounds of the invention includes ointments, powders, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed with a pharmaceutically acceptable carrier and any required preservative or buffer that may be required under aseptic conditions. Ophthalmic preparations, ear drops and eye drops are also considered to be within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the additional advantage of providing controlled delivery of compounds to the body. Such dosage forms can be prepared by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0176] In some embodiments, the present invention provides pharmaceutical compositions of the compounds and other excipients described herein. In some other embodiments, the present invention provides pharmaceutical compositions of the compounds of formula (A) and other excipients described herein.
[0177] In some embodiments, the pharmaceutical formulations of the present invention are prepared using excipients with low water or low moisture content and using dry or non-aqueous formulation methods to provide stable solid oral dosage forms of the active compounds.
[0178] Methods of treating diseases
[0179] The present invention provides a method for preventing and / or treating a disorder associated with proteasome mediation (such as cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis, or prostate), comprising the step of administering a compound of the present invention, or a crystalline form thereof, a pharmaceutically acceptable hydrate or solvate, or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition of the present invention to a subject in need of treatment. As used herein, the term "proteasome-mediated disorder" includes any disorder, disease, or condition caused by or characterized by an increase in proteasome expression or activity or requiring proteasome activity. The term "proteasome-mediated disorder" also includes any disorder, disease, or condition in which inhibition of proteasome activity is beneficial.
[0180] For example, the compounds of the present invention and their pharmaceutical compositions are useful for treating proteins regulated by proteasome activity (e.g., NFkB, p27 kip 、p21 WAF / CIPI 、p 53 ) mediated by inflammatory disorders (e.g., rheumatoid arthritis, inflammatory bowel disease, asthma, chronic obstructive pulmonary disease (COPD), osteoarthritis, skin diseases (e.g., atopic dermatitis, psoriasis)), vascular proliferative disorders (e.g., atherosclerosis, restenosis), proliferative eye diseases (e.g., diabetic retinopathy), benign proliferative disorders (e.g., hemangiomas), autoimmune diseases (e.g., multiple sclerosis, tissue and organ rejection), and inflammation associated with infection (e.g., immune response), neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, motor neuron disease, neuropathic pain, triplet repeat disorders, astrocytomas, and neurodegeneration due to alcoholic liver disease), ischemic injury (e.g., stroke), and cachexia (e.g., accelerated muscle protein breakdown associated with various physiological and pathological conditions (e.g., nerve damage, fasting, fever, acidosis, HIV infection, cancer afflictions, and certain endocrinopathy)).
[0181] The compounds and pharmaceutical compositions of the present invention are particularly useful for treating cancer. As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissues, and / or the ability to establish new bodies at ectopic sites. The term cancer includes, but is not limited to, solid tumors and hematogenous tumors. The term cancer encompasses diseases of the skin, tissues, organs, bones, cartilage, blood, and blood vessels. The term cancer further encompasses primary and metastatic cancers.
[0182] Non-limiting examples of solid tumors that can be treated with the disclosed proteasome inhibitors or pharmaceutical compositions include multiple myeloma, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer (including metastatic breast cancer), prostate cancer (including androgen-dependent and androgen-independent prostate cancer), kidney cancer (including metastatic renal cell carcinoma), hepatocellular carcinoma, lung cancer (including non-small cell lung cancer, bronchioloalveolar carcinoma, and lung adenocarcinoma, ovarian cancer (including progressive epithelial or primary peritoneal cancer), cervical cancer, gastric cancer, head and neck cancer (including squamous cell carcinoma of the head and neck), melanoma, neuroendocrine cancer (including metastatic neuroendocrine tumors), brain tumors (including gliomas, anaplastic oligodendrogliomas, adult glioblastoma multiforme, and adult anaplastic astrocytomas), bone cancer, and soft tissue sarcomas.
[0183] Non-limiting examples of hematological malignancies that can be treated with the disclosed proteasome inhibitors or pharmaceutical compositions include myeloid leukemia (AML); chronic myeloid leukemia (CML), including accelerated CML and CML blast phase (CML-BP); acute lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's disease (HD); non-Hodgkin's lymphoma (NHL), including follicular lymphoma and mantle cell lymphoma; B-cell lymphoma; T-cell lymphoma; multiple myeloma; Waldenstrom's macroglobulinemia; myelodysplastic syndrome (MDS), including refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), and RAEB in transition (RAEB-T); and myeloproliferative syndromes.
[0184] In certain embodiments, the compounds or pharmaceutical compositions of the invention are used to treat a patient having or at risk of developing or experiencing recurrence of a cancer selected from the group consisting of multiple myeloma and mantle cell lymphoma.
[0185] In certain embodiments, the compounds or pharmaceutical compositions of the invention are administered in combination with other therapeutic agents. Such other therapeutic agents may also inhibit the proteasome, or operate by a different mechanism. In certain embodiments, the other therapeutic agent is typically administered to a patient suffering from the disease or condition being treated. The proteasome inhibitors of the invention may be administered with the other therapeutic agent in a single dosage form or in separate dosage forms. When administered in separate dosage forms, the other therapeutic agent may be administered before, simultaneously with, or after administration of the proteasome inhibitor of the invention.
[0186] In certain embodiments, a proteasome inhibitor of Formula (A) or a pharmaceutical composition of a compound of Formula (A) is administered in conjunction with an anticancer agent. As used herein, the term "anticancer agent" refers to any agent that is administered to an individual with cancer for the purpose of treating cancer.
[0187] In some embodiments, the compounds of the present invention can be used in combination with drugs for treating cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis, and prostate disease. More preferably, the therapeutic drugs include but are not limited to: 5-fluorouracil, AV412, AvastinTM (avstin, bevacizumab), bexarotene, bortezomib, calcitriol, canertinib, capecitabine, carboplatin, celecoxib, cetuximab, CHR-2797, cisplatin, dasatinib, digoxin, enzastaurin, erlotinib, etoposide, everolimus, limus), fulvestrant, gefitinib, gemcitabine, genistein, imatinib, irinotecan, lapatinib, lenalidomide, letrozole, leucovorin, matuzumab, oxaliplatin, paclitaxel, panitumumab, pegfilgrastin, peglated interferon-α alfa-interferon, pemetrexed, Polyphenon E, satraplatin, sirolimus, sutent (sunitinib), sulindac, taxotere, temodar (temozomolomide), Torisel (temsirolimus), TGOI tipifarnib, trastuzumab, valproic acid, vinflunine, volociximab, vorinostat, and XL647.
[0188] Example
[0189] The compounds of the present invention can be prepared using methods disclosed herein and conventional variations in view of the apparent application and methods known in the art. In addition to teachings in the present application, conventional known synthetic methods can also be used. The synthesis of the compounds described herein can be achieved as described in the following examples. If commercially available, reagents can be purchased commercially, for example, from Sane Chemical Technology (Shanghai) Co., Ltd. or other chemical suppliers. Unless otherwise indicated, the starting materials for the following reactions can be obtained from commercial sources.
[0190] Example 1: Synthesis of Compound (A-1)
[0191] The synthesis route of compound (A-1) is as follows:
[0192]
[0193] Chlorinated compound (G) forms compound (F)
[0194]
[0195] Compound G (10.0 g, 52.4 mmol) and thionyl chloride (60 ml) were added to the reactor in sequence. The reaction solution was stirred at 80°C for about 4 hours, and the plate analysis was performed until the raw materials reacted completely. The reaction solution was cooled to room temperature, and the excess thionyl chloride was removed by vacuum rotary evaporation to finally obtain 10.2 g of liquid product, which was directly used for the next step.
[0196] Compound (F) is acylated to form compound (E)
[0197]
[0198] Glycine-2,2-d2 (1.65 g, 21.5 mmol) and sodium hydroxide (3.43 g, 85.9 mmol) were added to 30 ml THF to dissolve, and a tetrahydrofuran solution of compound F (3.0 g, 14.3 mmol, 8 ml) was added dropwise at 0°C. After addition, the mixture was stirred for 1 hour. After the reaction was completed by TLC, the pH was adjusted to acidic with dilute hydrochloric acid, and a white solid was precipitated. The mixture was extracted with ethyl acetate (40 ml × 2), and the organic phase was washed with saturated sodium chloride twice. The organic phase was collected, dried over anhydrous sodium sulfate, and the solvent was removed. The mixture was slurried with 20 ml petroleum ether / ethyl acetate (v / v) = 10:1 for 1 hour, filtered, and dried to obtain 2.9 g of a white solid product with a yield of 81%. LC-MS (APCI): m / z = 250.6 (M+1) + .
[0199] Compound (E) and compound (D) undergo peptide coupling reaction to form compound (C)
[0200]
[0201] Compound E (10.0 g, 40.0 mmol), compound D (15.1 g, 40.0 mmol), TBTU (12.8 g, 40.0 mmol) were added to 80 ml of anhydrous DMF to dissolve, cooled to 0 °C and then DIPEA (10.3 g, 80.0 mmol) was added dropwise. After the addition was completed, the reaction was stirred at low temperature for 1 hour. After the reaction was completed by TLC. 100 ml of water was added to quench the reaction, and the mixture was extracted with ethyl acetate (150 ml × 2). The organic phases were combined, and the organic phases were washed with 5% sodium chloride twice, saturated brine once, 2% potassium carbonate twice, 1% phosphoric acid once, and finally washed with saturated brine, dried over anhydrous sodium sulfate, and spin-dried to obtain 18.5 g of a white solid product with a yield of 93.2%. LC-MS (APCI): m / z = 497.3 (M+1) + .
[0202] Deprotection of compound (C) to form compound (B)
[0203]
[0204] Compound C (6.3 g, 12.7 mmol) and isobutylboric acid (3.36 g, 32.9 mmol) were added to 80 ml of methanol and 80 ml of n-hexane to dissolve, and then 1 N hydrochloric acid (19 ml, 19 mmol) was added. The reaction was stirred at room temperature for 15 h. After the reaction was completed by TLC, the methanol layer was separated and washed three times with n-hexane. Most of the methanol solution was concentrated, and then 2 N sodium hydroxide (30 ml) was added to form a salt, washed three times with dichloromethane, and the aqueous phase was adjusted to pH 2-3 with concentrated hydrochloric acid, and then extracted with dichloromethane (60 ml × 3), the organic phases were combined, washed with saturated brine, and the organic phases were dried and spin-dried to obtain a crude product. Then, 100 ml of n-heptane was used for slurrying for 2 hours, filtered, and dried to obtain 3.1 g of a white solid product with a yield of 67%.
[0205] Compound (B) reacts with citric acid to form compound (A-1)
[0206]
[0207] Compound B (1.0 g, 2.75 mmol) and citric acid (0.58 g, 3.03 mmol) were added to 1,4-dioxane (25 ml) solution in sequence. The reaction solution was stirred at 80°C for about 5 hours. The reaction was analyzed by spot plate analysis until the raw materials reacted completely. The solvent was dried by spin drying. Ethyl acetate (30 ml) was added at room temperature and stirred for 12 hours. Solids were precipitated and filtered to obtain 1.1 g of white solid product with a yield of 77%. Mp. 186-191°C, LC-MS (APCI): m / z = 519.2 (M+1)+ . 1 H NMR (400MHz, DMSO) δ12.12(s,2H),10.69(s,1H),9.09(s,1H),7.65(t,J=1.4Hz,1H),7. 55(d,J=1.4Hz,2H),2.95–2.51(m,5H),1.66(s,1H),1.22(s,2H),0.86(d,J=6.4Hz,6H), 13 C NMR (101MHz, DMSO) δ177.73, 175.96, 170.83, 170.48, 165.57, 136.91, 131.62, 131.5 3, 131.04, 129.03, 128.96, 76.16, 42.99, 40.86, 39.96, 38.20, 24.89, 23.66, 21.38.
[0208] Example 2: Formation of Compound (A-2)
[0209]
[0210] Compound B (1.0 g, 2.75 mmol) and citric acid (0.58 g, 3.03 mmol) were added to ethyl acetate (25 ml) in sequence. The reaction solution was stirred at 70°C for 10 minutes, then the heating was turned off, the temperature was naturally cooled to room temperature and stirred for 12 hours. Solids were precipitated and filtered to obtain 1.2 g of white solid product with a yield of 84%. Mp. 220-224°C, LC-MS (APCI): m / z = 519.2 (M+1) + . 1 H NMR (400MHz, DMSO) δ12.12(s,2H),10.69(s,1H),9.09(s,1H),7.65(t,J=1.4Hz,1H),7.55( d,J=1.4Hz,2H),2.95–2.51(m,5H),1.67(s,1H),1.36–1.17(m,2H),0.86(d,J=6.5Hz,6H), 13 C NMR (101MHz, DMSO) δ177.75, 175.91, 170.80, 170.41, 165.58, 136.91, 131.63, 131.5 3, 131.04, 129.05, 128.96, 76.20, 42.98, 40.89, 38.96, 38.16, 24.90, 23.60, 21.34.
[0211] Compound (A-2) can also be prepared by the following method:
[0212] Method 2: Compound B (0.2 g, 0.55 mmol) and citric acid (0.12 g, 0.61 mmol) were added to dichloromethane (15 ml) solution in sequence, and the reaction solution was stirred at 45°C for about 5 h, and the plate analysis was performed until the raw materials reacted completely, the solvent was spin-dried, ethyl acetate was added at room temperature until the solid was completely dissolved, and then stirred at room temperature for 12 h, solid precipitated, and suction filtered to obtain 0.22 g of white solid product, with a yield of 76%. Mp. 220-224°C, LC-MS (APCI): m / z = 519.2 (M+1) + .
[0213] Method 3: Compound B (0.2 g, 0.55 mmol) and citric acid (0.12 g, 0.61 mmol) were added to tetrahydrofuran (15 ml) solution in sequence, and the reaction solution was stirred at 65°C for about 5 h, and the plate analysis was performed until the raw materials reacted completely, the solvent was dried, ethyl acetate was added at room temperature until the solid was completely dissolved, and then stirred at room temperature for 12 h, solid was precipitated, and suction filtration was performed to obtain 0.24 g of white solid product, with a yield of 83%. Mp. 222-226°C, LC-MS (APCI): m / z = 519.2 (M+1) + .
[0214] Method 4: Compound B (0.2 g, 0.55 mmol) and citric acid (0.12 g, 0.61 mmol) were added to acetone (15 ml) solution in sequence, and the reaction solution was stirred at 60°C for about 5 h, and the plate analysis was performed until the raw materials reacted completely, the solvent was spin-dried, and ethyl acetate was added at room temperature until the solid was completely dissolved, and the mixture was stirred at room temperature for 12 h. The solid was precipitated and filtered to obtain 0.21 g of a white solid product with a yield of 73%. Mp. 220-224°C, LC-MS (APCI): m / z = 519.2 (M+1) + .
[0215] Method 5: Compound B (0.2 g, 0.55 mmol) and citric acid (0.12 g, 0.61 mmol) were added to methyl tert-butyl ether (15 ml) solution in sequence, and the reaction solution was stirred at 56°C for about 5 hours, and the plate analysis was performed until the raw materials reacted completely, the solvent was spin-dried, and ethyl acetate was added at room temperature until the solid was completely dissolved, and stirred at room temperature for 12 hours, and the solid was precipitated and filtered to obtain 0.24 g of a white solid product with a yield of 83%. Mp. 222-224°C, LC-MS (APCI): m / z = 519.2 (M+1) + .
[0216] Method 6: Compound B (0.2 g, 0.55 mmol) and citric acid (0.12 g, 0.61 mmol) were added to ethylene glycol dimethyl ether (15 ml) solution in sequence, and the reaction solution was stirred at 80°C for about 5 h, and the plate analysis was performed until the raw materials reacted completely, the solvent was dried, and ethyl acetate was added at room temperature until the solid was completely dissolved, and the mixture was stirred at room temperature for 12 h, and the solid was precipitated and filtered to obtain 0.20 g of a white solid product with a yield of 70%. Mp. 220-226°C, LC-MS (APCI): m / z = 519.2 (M+1) + .
[0217] Example 3: Crystalline form of the compound of formula (A)
[0218] The crystalline form of compound (A) was analyzed by XRPD, DSC and TGA. XRPD patterns were collected using a PANalytical X'Pert PROMPD diffractometer with the following experimental settings: 40 kV, 40 mA, Scanning range 4-40°2 θ , step size 0.02°2 θ DSC analysis and TGA analysis were performed on a NETZSCH STA449F3 STA449F3A-1029-M differential scanning calorimeter-thermogravimetric analyzer using about 3-6 mg of sample in the range of 25°C-400°C at a heating rate of 10°C / min.
[0219] 1. Crystalline Form I of Compound of Formula (A-1)
[0220] The crystalline form I of the compound of formula (A-1) was prepared as in Example 1, and the crystalline form was obtained in an ethyl acetate solvent system. The crystalline form I of the compound of formula (A-1) was characterized by XRPD, DSC and TGA. The XRPD spectrum is shown in Figure 1 The XRPD pattern analysis data are shown in Table 1. TGA does not show any weight loss below about 50°C, and a weight loss of about 0.9% is observed from about 50°C to about 200°C, and then decomposition occurs ( Figure 2 The DSC thermogram shows a sharp endotherm at about 197.9°C, followed by a sharp endotherm at about 249.7°C ( Figure 2 ).
[0221] Table 1: XRPD spectrum analysis data of the crystalline form I of the compound of formula (A-1)
[0222]
[0223]
[0224] 2. Crystalline Form I of Compound of Formula (A-2)
[0225] The crystalline form I of the compound of formula (A-2) was prepared as in Example 1, and the crystalline form was obtained in an ethyl acetate solvent system. The crystalline form I of the compound of formula (A-2) was characterized by XRPD, DSC and TGA. The XRPD spectrum is shown in Figure 3 The XRPD pattern analysis data are shown in Table 2. TGA does not show any weight loss below about 50°C, and a weight loss of about 0.9% is observed from about 50°C to about 200°C, and then decomposition occurs ( Figure 4 ). The DSC thermogram shows sharp endotherms at about 224.6°C, 237.0°C, and then at about 253.5°C ( Figure 4 ).
[0226] Table 2: XRPD spectrum analysis data of the compound of formula (A-2) Form I
[0227]
[0228]
[0229] Example 4: Antiproliferation assay
[0230] The in vitro antiproliferative activity of the compounds of the present invention on tumor cells cultured in vitro was detected by MTS method.
[0231] Cell line: Myeloma cells MM.1s (purchased from American Type Culture Collection (ATCC)) were cultured in RPMI1640 medium containing 10% fetal bovine serum, 100 U / ml penicillin, and 100 μg / ml streptomycin.
[0232] Reagents and consumables: RPMI-1640 (GIBCO, catalog number A10491-01); fetal bovine serum (GIBCO, catalog number 10099141); 0.25% trypsin-EDTA (GIBCO, catalog number 25200); penicillin-streptomycin; liquid (GIBCO, catalog number 15140-122); DMSO (Sigma, catalog number D2650); MTS test kit (Promega, catalog number G3581), 96-well plate (Corning, catalog number 3365).
[0233] Specific experimental methods:
[0234] Compound preparation: The test compound was dissolved in DMSO to prepare a 20 mM stock solution and stored at -20°C. It was diluted 3-fold and 10-fold with DMSO in a gradient. When adding the drug, it was diluted 4-fold with cell culture medium.
[0235] MTS cell viability assay: Digest the cells in the logarithmic growth phase with 0.25% trypsin-EDTA, inoculate 150 μl in a 96-well plate at an optimized density, and add the compound diluted 4 times with culture medium 24 hours later, 50 μl / well (generally ten concentrations are selected: 100, 33.3, 11.1, 3.70, 1.23, 0.412, 0.137, 0.0457, 0.0152, 0.00508 μM). The wells with the same volume of 0.5% DMSO were used as controls. After the cells were cultured for 72 hours, MTS was used to detect cell viability.
[0236] Specific operation: For adherent cells, discard the culture medium, and add a mixture of 20 μL MTS and 100 μL culture medium to each well. Place in an incubator and continue to culture for 1-4 hours. Detect OD490 and use OD650 as a reference. Use GraphPad Prism software to create a dose-effect curve and calculate IC 50 .
[0237] When tested in this assay, both Compound A-1 and Compound A-2 exhibited potent and superior inhibitory activity compared to the non-deuterated compounds, respectively. The results are shown in Table 3 below.
[0238] Table 3: In vitro antiproliferative activity test of the compound of formula (A)
[0239]
[0240] Example 5: Liver microsomal stability test of the compound of formula (A)
[0241] Microsome experiment: human liver microsomes: 0.5 mg / mL, Xenotech; rat liver microsomes: 0.5 mg / mL, Xenotech; coenzyme (NADPH / NADH): 1 mM, Sigma Life Science; magnesium chloride: 5 mM, 100 mM phosphate buffer (pH 7.4).
[0242] Preparation of stock solution: accurately weigh a certain amount of powder of the example compound and dissolve it in DMSO to 5 mM.
[0243] Preparation of phosphate buffer (100mM, pH7.4): Mix 150mL of 0.5M potassium dihydrogen phosphate solution and 700mL of 0.5M potassium dihydrogen phosphate solution, adjust the pH value of the mixture to 7.4 with 0.5M potassium dihydrogen phosphate solution, dilute 5 times with ultrapure water before use, add magnesium chloride to obtain phosphate buffer (100mM), which contains 100mM potassium phosphate, 3.3mM magnesium chloride, and pH is 7.4.
[0244] Prepare NADPH regeneration system solution (containing 6.5 mM NADP, 16.5 mM G-6-P, 3 U / mL G-6-PD, 3.3 mM magnesium chloride) and place on wet ice before use.
[0245] Prepare stop solution: acetonitrile solution containing 50 ng / mL propranolol hydrochloride and 200 ng / mL tolbutamide (internal standard). Take 25057.5 μL phosphate buffer (pH 7.4) into a 50 mL centrifuge tube, add 812.5 μL human liver microsomes, mix well, and obtain a liver microsome dilution with a protein concentration of 0.625 mg / mL. Take 25057.5 μL phosphate buffer (pH 7.4) into a 50 mL centrifuge tube, add 812.5 μL SD rat liver microsomes, mix well, and obtain a liver microsome dilution with a protein concentration of 0.625 mg / mL.
[0246] Sample incubation: Dilute the stock solution of the corresponding compound to 0.25 mM with an aqueous solution containing 70% acetonitrile as the working solution for later use. Take 398 μL of the human liver microsome or rat liver microsome dilution solution and add it to a 96-well incubation plate (N=2), add 2 μL of the 0.25 mM working solution and mix well.
[0247] Determination of metabolic stability: Add 300 μL of pre-cooled stop solution to each well of a 96-well deep-well plate and place it on ice as a stop plate. Place the 96-well incubation plate and NADPH regeneration system in a 37°C water bath, shake at 100 rpm, and pre-incubate for 5 minutes. Take out 80 μL of incubation solution from each well of the incubation plate and add it to the stop plate, mix well, and add 20 μL of NADPH regeneration system solution as the 0-min sample. Add 80 μL of NADPH regeneration system solution to each well of the incubation plate to start the reaction and start timing. The reaction concentration of the corresponding compound is 1 μM and the protein concentration is 0.5 mg / mL. At 10, 30, and 90 minutes of reaction, take 100 μL of the reaction solution, add it to the stop plate, and vortex for 3 minutes to stop the reaction. Centrifuge the stop plate at 5000×g and 4°C for 10 minutes. 100 μL of supernatant was taken into a 96-well plate pre-added with 100 μL of distilled water, mixed well, and the sample was analyzed by LC-MS / MS.
[0248] Data analysis: The peak areas of the corresponding compounds and internal standards were detected by LC-MS / MS system, and the peak area ratio of the compounds to the internal standard was calculated. The slope was measured by plotting the natural logarithm of the percentage of the remaining amount of the compound against time, and t was calculated according to the following formula: 1 / 2 and CL int , where V / M is equal to 1 / protein concentration.
[0249] t1 / 2 (min); CL int (μL / min / mg).
[0250] The compound of formula (A) of the present invention and its non-deuterated compound Ixazomib were tested and compared to evaluate their metabolic stability in human and rat liver microsomes. In the human and rat liver microsome experiments, the half-life of the compound of formula (A-1) and the compound of formula (A-2) was significantly longer than that of Ixazomib, and the clearance rate was also significantly lower than that of Ixazomib.
[0251] Example 6: Pharmacokinetics in rats
[0252] Six male Sprague-Dawley rats, 7-8 weeks old, weighing about 210 g, were divided into two groups, 3 rats in each group, and a single dose of the compound (0.3 mg / kg intravenously; 2 mg / kg orally) was administered intravenously or orally to compare their pharmacokinetic differences.
[0253] Rats were fed with standard diet and given water. Fasting began 16 hours before the experiment. Drugs were dissolved with PEG400 and dimethyl sulfoxide. Blood was collected from the orbit at 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration.
[0254] The rats were briefly anesthetized by inhalation of ether, and 300 μL of blood samples were collected from the orbits into test tubes. The test tubes contained 30 μL of 1% heparin saline solution. Before use, the test tubes were dried at 60°C overnight. After the last time point of blood sampling was completed, the rats were killed under ether anesthesia.
[0255] After blood sample collection, gently invert the test tube at least 5 times to ensure sufficient mixing and place on ice. The blood sample is centrifuged at 5000rpm for 5 minutes at 4°C to separate plasma from red blood cells. Use a pipette to aspirate 100μL of plasma into a clean plastic centrifuge tube and mark the name of the compound and time point. The plasma is stored at -80°C before analysis. The concentration of the compound of the present invention in plasma is determined by LC-MS / MS. Pharmacokinetic parameters are calculated based on the blood drug concentration of each animal at different time points.
[0256] The experiment shows that the compound of the present invention has better pharmacokinetic properties in animals, and thus has better therapeutic effects. The results are shown in Table 4 below.
[0257] Table 4: Pharmacokinetics of compounds of formula (A-1) and (A-2) in rats
[0258]
[0259] Example 7: Pharmaceutical composition
[0260] The drugs in the present invention may be in the form of but not limited to the following pharmaceutical compositions:
[0261] Pharmaceutical composition 1
[0262] Element Amount per unit dose (mg) Dosage (% w / w or w / w) Compound of formula (A) 4 1.3 Silicified Microcrystalline Cellulose 292.4 97.5 talcum powder 0.6 0.2 Magnesium Stearate 3 1 Content weight 300 100
[0263] Pharmaceutical composition 2
[0264] Element Amount per unit dose (mg) Dosage (%w / w or w / w) Compound of formula (A) 4 1.3 Microcrystalline Cellulose 231.8 77.8 Pregelatinized starch 60 20 Silicon dioxide 1.2 0.1 Magnesium Stearate 3 1 Content weight 300 100
[0265] Pharmaceutical composition 3
[0266] Element Amount per unit dose (mg) Dosage (% w / w or w / w) Compound of formula (A) 4 1.3 Microcrystalline Cellulose 246.8 82.3 Mannitol 45 15 talcum powder 1.2 0.4 Magnesium Stearate 3 1 Content weight 300 100
[0267] Pharmaceutical composition 4
[0268] Element Amount per unit dose (mg) Dosage (% w / w or w / w) Compound of formula (A) 3 1.5 Microcrystalline Cellulose 150 75 Corn starch 45 22.5 Magnesium Stearate 2 1 Content weight 200 100
[0269] Pharmaceutical composition 5
[0270] Element Amount per unit dose (mg) Dosage (% w / w or w / w) Compound of formula (A) 3 1.5 Mannitol 120 60 lactose 45 37.5 Magnesium Stearate 2 1 Content weight 200 100
[0271] Pharmaceutical composition 6
[0272] Element Amount per unit dose (mg) Dosage (% w / w or w / w) Compound of formula (A) 3 1.5 Mannitol 100 50 Microcrystalline Cellulose 95 47.5 Magnesium Stearate 2 1 Content weight 200 100
[0273] Pharmaceutical composition 7
[0274]
[0275] Pharmaceutical composition 8
[0276] Element Amount per unit dose (mg) Dosage (% w / w or w / w) Compound of formula (A) 2.3 1.15 Silicified Microcrystalline Cellulose 155 77.5 Mannitol 40 20 talcum powder 0.7 0.35 Magnesium Stearate 2 1 Content weight 200 100
[0277] According to conventional methods, the above pharmaceutical composition is mixed evenly according to proportions and then packed into opaque white gelatin capsules.
[0278] In this embodiment, "the compound of formula (A)" includes compound (A-1) and compound (A-2).
[0279] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.
[0280] In summary, the present invention relates to the following technical solutions:
[0281] 1. A method for preparing a compound of formula (A) or a crystalline form thereof:
[0282]
[0283] wherein n and m are independently selected from 0 or 1; and n and m are different,
[0284] The method comprises the following steps:
[0285] a) reacting a compound of formula (B) with citric acid to form a compound of formula (A):
[0286]
[0287] b) optionally crystallizing the compound of formula (A).
[0288] 2. The method according to technical solution 1, wherein the solvent in step a) is dioxane, and the product compound of formula (A) is a compound of formula (A-1)
[0289]
[0290] 3. The method according to technical solution 2, wherein the solvent in step a) is 1,4-dioxane.
[0291] 4. The method according to technical solution 2, wherein the reaction temperature of step a) is 40°C to 101.1°C.
[0292] 5. The method according to technical solution 2, wherein the reaction temperature of step a) is 80°C.
[0293] 6. The method according to any one of technical solutions 2-5, wherein step a) is to add the compound of formula (B) and citric acid to a solvent, and the reaction is stirred at 80° C. until the raw materials react completely.
[0294] 7. The method according to any one of technical solutions 2-6, wherein in step b), the solvent of step a) is removed, and ethyl acetate is added at room temperature and stirred until a solid is precipitated.
[0295] 8. The method according to technical solution 7, wherein in step b), ethyl acetate is added at room temperature and stirred for 12 hours, solid is precipitated and filtered.
[0296] 9. The method according to technical solution 1, wherein the reaction solvent in step a) comprises methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, ethyl acetate, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dichloromethane, toluene, heptane, methyl-cyclohexane, ethylene glycol dimethyl ether, methyl tert-butyl ether and mixtures thereof,
[0297] The product formula (A) compound is the formula (A-2) compound
[0298]
[0299] 10. The method according to technical solution 9, wherein the reaction temperature of step a) is 40°C to 80°C.
[0300] 11. The method according to any one of technical solutions 9-10, wherein step a) is to add the compound of formula (B) and citric acid to a solvent, and stir the reaction until the raw materials react completely.
[0301] 12. The method according to any one of technical solutions 9 to 11, wherein in step b), the solvent of step a) is removed, and ethyl acetate is added at room temperature and stirred until a solid is precipitated.
[0302] 13. The method according to technical solution 9, wherein the solvent in step a) is ethyl acetate.
[0303] 14. The method according to technical solution 13, wherein the reaction temperature of step a) is 70°C.
[0304] 15. The method according to technical solution 13, wherein the compound of formula (B) and citric acid are added to a solvent, stirred at 70°C for 10 minutes, cooled to room temperature and stirred until a solid precipitates.
[0305] 16. The method according to technical solution 12 or 15, wherein the temperature is lowered to room temperature and stirred for 12 hours, solids are precipitated and filtered.
[0306] 17. A compound of formula (A) or a crystal thereof prepared by any method of Technical Schemes 1 to 16.
[0307] 18. Crystalline Form I of the compound of formula (A-1),
[0308]
[0309] 19. Crystalline Form I of the compound of formula (A-1),
[0310]
[0311] The invention is characterized in that the X-ray powder diffraction pattern includes the following peaks: 6.361, 8.06, 16.137, 17.56, 19.001, 20.201, 24.88, 25.358°2θ±0.2°2θ, and the wavelength used on the diffractometer is Cu-Kα radiation measurement.
[0312] 20. According to the technical solution 19, the crystalline form I of the compound of formula (A-1) is characterized in that the X-ray powder diffraction pattern includes the following peaks: 6.361, 8.06, 10.599, 14.80, 16.137, 17.56, 19.001, 20.201, 21.02, 24.88, 25.358°2θ±0.2°2θ, and the wavelength used on the diffractometer is Cu-Kα radiation measurement.
[0313] 21. According to the crystalline form I of the compound of formula (A-1) of technical solution 19, it is characterized in that the X-ray powder diffraction pattern includes the following peaks: 6.361, 8.06, 10.079, 10.599, 12.719, 13.356, 14.8, 15.319, 16.137, 17.119, 17.56, 18.04, 19.001, 20.201, 21.02, 22.041, 24.88, 25.358, 26.241, 26.618, 27.901, 32.56, 33.94, 35.163, 28. θ ±0.2 θ 2 θ , which uses a wavelength of Cu-Kα radiation measurement.
[0314] 22. According to the crystalline form I of the compound of formula (A-1) of technical solution 19, wherein the diffraction pattern is substantially as follows Figure 1 shown.
[0315] 23. The crystalline form I of the compound of formula (A-1) according to technical solution 19, which is characterized by a differential scanning calorimetry (DSC) curve with endotherms at about 197.9°C and about 249.7°C.
[0316] 24. According to the crystalline form I of the compound of formula (A-1) of technical solution 19, the DSC curve thereof is substantially as follows Figure 2 shown.
[0317] 25. Crystalline Form I of the compound of formula (A-2),
[0318]
[0319] The invention is characterized in that the X-ray powder diffraction pattern includes the following peaks: 5.740, 7.517, 11.458, 19.438, 19.801 and 22.262°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
[0320] 26. According to the technical solution 25, the crystalline form I of the compound of formula (A-2) is characterized in that the X-ray powder diffraction pattern includes the following peaks: 5.740, 7.517, 11.458, 12.439, 16.578, 19.438, 19.801, 22.262 and 22.999°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
[0321] 27. According to the crystalline form I of the compound of formula (A-2) of technical solution 25, it is characterized in that the X-ray powder diffraction pattern includes the following peaks: 5.74, 7.517, 11.458, 11.819, 12.439, 14.278, 16.578, 17.2, 18.119, 19.438, 19.801, 20.279, 21.621, 22.262, 22.999, 26.34, 29.262, 29.759, 31.38, 34.2 and 34.840°2 θ ±0.2 θ 2 θ , which uses a wavelength of Cu-Kα radiation measurement.
[0322] 28. According to the crystalline form I of the compound of formula (A-2) of technical solution 25, wherein the diffraction pattern is substantially as follows Figure 3 shown.
[0323] 29. The crystalline form I of the compound of formula (A-2) according to technical solution 25, which is characterized by a differential scanning calorimetry (DSC) curve comprising endotherms at about 224.6°C, about 237.0°C and about 253.5°C.
[0324] 30. According to the crystalline form I of the compound of formula (A-2) of technical solution 25, the DSC curve thereof is substantially as follows Figure 4 shown.
[0325] 31. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (A) or its crystal as described in Technical Scheme 17, a compound of formula (A-1) of Technical Scheme 18, or a crystalline form I of a compound of formula (A-1) of any one of Technical Schemes 19-24, or a crystalline form I of a compound of formula (A-2) of any one of Technical Schemes 25-30.
[0326] 32. Use of the compound of formula (A) or its crystal according to technical solution 17, the compound of formula (A-1) according to technical solution 18, or the crystal form I of the compound of formula (A-1) according to any one of technical solutions 19-24, or the crystal form I of the compound of formula (A-2) according to any one of technical solutions 25-30 in the preparation of drugs for treating and preventing proteasome-related diseases.
[0327] 33. Use of the compound of formula (A) or its crystal according to technical solution 17, the compound of formula (A-1) according to technical solution 18, or the crystal form I of the compound of formula (A-1) according to any one of technical solutions 19-24, or the crystal form I of the compound of formula (A-2) according to any one of technical solutions 25-30 in the preparation of drugs for treating and preventing cancer, cardiovascular disease, inflammation, immune disease, kidney disease, angiogenesis or prostate disease.
[0328] 34. According to the use of technical solution 33, the cancer is selected from multiple myeloma, non-small cell lung cancer, uterine cancer, rectal cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, solid tumors, kidney cancer, blood cancer, liver cancer, gastric cancer, or pancreatic cancer.
Claims
1. Crystalline Form I of the compound of formula (A-1), Features The X-ray powder diffraction pattern includes the following peaks: 6.361°2θ±0.2°2θ, 8.06°2θ±0.2°2θ, 16.137°2θ±0.2°2θ, 17.56°2θ±0.2°2θ, 19.001°2θ±0.2°2θ, 20.201°2θ±0.2°2θ, 24.88°2θ±0.2°2θ, 25.358°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
2. According to claim 1, the compound of formula (A-1) crystalline form I, characterized in that The X-ray powder diffraction pattern includes the following peaks: 6.361°2θ±0.2°2θ, 8.06°2θ±0.2°2θ, 10.599°2θ±0.2°2θ, 14.80°2θ±0.2°2θ, 16.137°2θ±0.2°2θ, 17.56°2θ±0.2°2θ, 19.001°2θ±0.2°2θ, 20.201°2θ±0.2°2θ, 21.02°2θ±0.2°2θ, 24.88°2θ±0.2°2θ, 25.358°2θ±0.2°2θ, which is measured on a diffractometer using a wavelength of Cu-Kα radiation measurement.
3. According to claim 1, the compound of formula (A-1) crystalline form I, characterized in that The X-ray powder diffraction pattern includes the following peaks: 6.361°2θ±0.2°2θ, 8.06°2θ±0.2°2θ, 10.079°2θ±0.2°2θ, 10.599°2θ±0.2°2θ, 12.719°2θ±0.2°2θ, 13.356°2θ±0.2°2θ, 14.8°2θ±0.2°2θ, 15.319°2θ±0.2°2θ, 16.137°2θ±0.2°2θ, 17.119°2θ±0.2°2θ, 17.56°2θ±0.2°2θ, 18.04°2θ±0.2°2θ, 19.001°2θ±0.2°2θ, 20.201°2θ±0.2°2θ, 21.02°2θ±0.2°2θ, 22.041°2θ±0.2°2θ, 24.88°2θ±0.2°2θ, 25.358°2θ±0.2°2θ, 26.241°2θ±0.2°2θ, 26.618°2θ±0.2°2θ, 27.901°2θ±0.2°2θ, 32.56°2θ±0.2°2θ, 33.94°2θ±0.2°2θ, 35.163°2θ±0.2°2θ, and the wavelength used on the diffractometer is Cu-Kα radiation measurement.
4. According to claim 1, the compound of formula (A-1) crystalline form I, characterized in that The X-ray powder diffraction pattern includes the following peaks and intensities:
5. According to claim 1, the compound of formula (A-1) crystalline form I, characterized in that A differential scanning calorimetry curve containing endotherms at 197.9°C and 249.7°C.
6. Use of the crystalline form I of the compound of formula (A-1) according to any one of claims 1 to 5 in the preparation of drugs for treating and preventing proteasome-related diseases.
7. Use of the crystalline form I of the compound of formula (A-1) according to any one of claims 1 to 5 in the preparation of a medicament for treating and preventing cancer, cardiovascular disease, inflammation, immune disease, kidney disease or prostate disease.
8. The use according to claim 7, wherein the cancer is a solid tumor.
9. The use according to claim 7, wherein the cancer is selected from multiple myeloma, non-small cell lung cancer, uterine cancer, colorectal cancer, brain cancer, head cancer, neck cancer, skin cancer, prostate cancer, breast cancer, kidney cancer, blood cancer, liver cancer, stomach cancer or pancreatic cancer.
